$BINV News
Last published 2y ago
- 2y agoCASIBINVCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaPR NewswireCASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative...
- 5y agoBINVBioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancerPR NewswireBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation ...
- 5y agoBINVBioInvent International's Annual Report 2020 publishedPR NewswireBioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2020 is published and available at the...
- 5y agoBINVBioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808PR NewswireBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the...
- 5y agoBINVChange in the number of shares and votes in BioInvent International ABPR NewswireBioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per March 31, 2021 amounts to ...
- 5y agoBINVResolution at the Extraordinary General Meeting in BioInvent on March 23, 2021PR NewswireBioInvent International AB's (publ) ("BioInvent") (Nasdaq Stockholm: BINV) Extraordinary General Meeting (the "EGM") today resolved to approve the...
- 5y agoBINVBioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021PR NewswireBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), today announces the publication of proof-of-concept data on a novel, fully human...
- 5y agoBINVBioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumorsPR NewswireBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and...
- 5y agoBINVTransgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid TumorsBusiness WireSTRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: